CSIMarket
 


Nighthawk Biosciences inc   (NHWK)
Other Ticker:  
 

Nighthawk Biosciences Inc 's Working Capital Ratio

NHWK's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 0.99 a new company low.

Within Major Pharmaceutical Preparations industry 396 other companies have achieved higher Working Capital Ratio than Nighthawk Biosciences Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 2829 to 3045.

Explain Working Capital Ratio
How much in Current Assets NHWK´s has?
What is the value of NHWK´s Current Liabilities?


NHWK Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 69.46 % 1.38 % 228.9 % 282.09 % 339.2 %
Y / Y Current Assets Change -63.62 % -71.3 % -60.32 % -49.61 % -40.56 %
Working Capital Ratio MRQ 0.99 1.49 1.97 2.78 4.6
NHWK's Total Ranking # 3045 # 2829 # 2174 # 1733 # 1004
Seq. Current Liabilities Change 59.62 % -12.23 % -3.09 % 24.82 % -4.5 %
Seq. Current Assets Change 6.14 % -33.69 % -31.36 % -24.7 % -16.27 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 397
Healthcare Sector # 813
Overall Market # 3045


Working Capital Ratio Statistics
High Average Low
43.95 10.77 0.99
(Mar 31 2021)   (Sep 30 2023)




Financial Statements
Nighthawk Biosciences Inc 's Current Liabilities $ 24 Millions Visit NHWK's Balance sheet
Nighthawk Biosciences Inc 's Current Assets $ 24 Millions Visit NHWK's Balance sheet
Source of NHWK's Sales Visit NHWK's Sales by Geography


Cumulative Nighthawk Biosciences Inc 's Working Capital Ratio

NHWK's Working Capital Ratio for the trailling 12 Months

NHWK Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 69.46 % 1.38 % 228.9 % 282.09 % 339.2 %
Y / Y Current Assets TTM Growth -63.62 % -71.3 % -60.32 % -49.61 % -40.56 %
Working Capital Ratio TTM 1.74 2.66 3.54 5.34 8.37
Total Ranking TTM # 2029 # 1463 # 1171 # 903 # 564
Seq. Current Liabilities TTM Growth 59.62 % -12.23 % -3.09 % 24.82 % -4.5 %
Seq. Current Assets TTM Growth 6.14 % -33.69 % -31.36 % -24.7 % -16.27 %


On the trailing twelve months basis Due to jump in Current Liabilities in the III Quarter 2023 to $24.49 millions, cumulative Working Capital Ratio decreased to 1.74 below the Nighthawk Biosciences Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 496 other companies have achieved higher Working Capital Ratio than Nighthawk Biosciences Inc . While Working Capital Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2243 to 3723.

Explain Working Capital Ratio
How much in Current Assets NHWK´s has?
What is the value of NHWK´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 497
Healthcare Sector # 1035
Within the Market # 3045


trailing twelve months Working Capital Ratio Statistics
High Average Low
36.29 10.69 1.42
(Sep 30 2021)   (Mar 31 2018)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Vyne Therapeutics Inc   2.72 $ 17.511  Millions$ 6.449  Millions
Seres Therapeutics Inc   2.71 $ 214.394  Millions$ 79.225  Millions
Universe Pharmaceuticals Inc  2.68 $ 36.810  Millions$ 13.754  Millions
Revelation Biosciences Inc   2.62 $ 14.147  Millions$ 5.400  Millions
Clever Leaves Holdings Inc   2.62 $ 17.934  Millions$ 6.847  Millions
Eton Pharmaceuticals Inc   2.61 $ 27.157  Millions$ 10.393  Millions
Vincerx Pharma Inc   2.58 $ 22.818  Millions$ 8.846  Millions
Pfizer Inc  2.56 $ 74,012.000  Millions$ 28,932.000  Millions
Hcw Biologics Inc   2.56 $ 13.848  Millions$ 5.417  Millions
Biomarin Pharmaceutical Inc  2.54 $ 2,955.308  Millions$ 1,163.223  Millions
Bioxcel Therapeutics Inc   2.51 $ 98.738  Millions$ 39.408  Millions
Galera Therapeutics Inc   2.47 $ 31.245  Millions$ 12.630  Millions
Heron Therapeutics Inc   2.43 $ 193.979  Millions$ 79.745  Millions
Societal Cdmo Inc   2.43 $ 49.785  Millions$ 20.524  Millions
Omeros Corp  2.39 $ 351.338  Millions$ 147.176  Millions
Acadia Pharmaceuticals Inc   2.38 $ 499.170  Millions$ 209.603  Millions
Madrigal Pharmaceuticals Inc   2.37 $ 235.469  Millions$ 99.152  Millions
Ultragenyx Pharmaceutical Inc   2.36 $ 599.188  Millions$ 253.978  Millions
Iterum Therapeutics Plc  2.35 $ 38.527  Millions$ 16.396  Millions
Mannkind Corporation  2.34 $ 225.575  Millions$ 96.374  Millions
Entrada Therapeutics Inc   2.32 $ 383.043  Millions$ 165.433  Millions
Lftd Partners Inc   2.30 $ 18.874  Millions$ 8.197  Millions
Conduit Pharmaceuticals Inc   2.27 $ 10.443  Millions$ 4.603  Millions
Oramed Pharmaceuticals Inc   2.25 $ 175.705  Millions$ 78.175  Millions
Mallinckrodt Plc  2.24 $ 1,787.500  Millions$ 799.000  Millions
Acurx Pharmaceuticals inc   2.22 $ 7.158  Millions$ 3.223  Millions
Eli Lilly And Company  2.20 $ 23,007.000  Millions$ 10,475.900  Millions
Renovorx Inc   2.19 $ 3.519  Millions$ 1.605  Millions
Nature s Sunshine Products inc   2.19 $ 160.223  Millions$ 73.312  Millions
Vaxxinity Inc   2.15 $ 46.356  Millions$ 21.561  Millions

Date modified: 2023-11-21T19:00:41+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com